Bicara Therapeutics (BCAX) shares plunged 44% after the company said late Thursday that updated interim data from its Phase 1/1b trial of ficerafusp alfa with pembrolizumab in patients with first-line recurrent/metastatic head and neck squamous cell carcinoma showed a 64% objective response rate, including several complete responses. Median overall survival and duration of response were not yet reached as of the December 2024 data cutoff.
More than 5.19 million shares traded intraday compared with a daily average of about 588,000.
Deckers Outdoor's (DECK) strong fiscal Q4 results were overshadowed by sales growth deceleration at its Hoka sneaker brand and potential demand weakness from price increases, prompting KeyBanc Capital Markets to downgrade the footwear and apparel company's stock.
Shares of Deckers sank 18% following an increase in intraday trading volume to over 13.9 million from a daily average of about 3.2 million.
Ross Stores (ROST) overnight warned that elevated tariffs could pressure profitability, noting that over half its merchandise originates from China despite limited direct imports. Citing ongoing macroeconomic uncertainty and shifting trade policies, the company withdrew its full-year sales and earnings guidance.
Shares declined 10%, with intraday trading volume rising to over 13.1 million versus a daily average of about 3.2 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。